TP53 and carcinoma: Sánchez-Tomé et al. likewise reported differences in the immunoprofile of FCCTX carcinomas (27 cases) – and Lynch syndrome carcinomas (18 cases) based on markers selected to analyze colorectal carcinogenesis, including SMAD4, COX2, MUC1, and P53 [13].